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Dear Sir,
We read with interest the comments of Dr. Tfelt-Hansen
[1] on the two recently published randomized controlled
trials comparing patients’ preference (primary end-point)
and efﬁcacy (secondary end-points) of frovatriptan with
respect to rizatriptan [2] and almotriptan [3]. In both
studies, frovatriptan showed similar preference and short-
term efﬁcacy outcomes (pain relief and pain free episodes
at 2 h) with respect to the other two triptans.
The principal concern of Dr. Tfelt-Hansen was the very
early use of frovatriptan in these studies, making their
results hardly comparable with those of previous random-
ized controlled trials [4–6], where patients waited until the
headache was moderate or severe. In our studies [2, 3],
patients were instructed to take one dose of study medi-
cation as early as possible after the onset of migraine and to
treat at least 1 out of three attacks, but severity of headache
at the time of drug intake was in the majority of patients
moderate or severe. As a matter of fact, in the study by
Savi et al. [2] 78% of attacks treated with frovatriptan and
74% of those treated with rizatriptan were of moderate or
severe intensity. In the study by Bartolini et al. [3] 80% of
overall treated attacks were of moderate or severe intensity
and 97% of patients had at least one moderate or severe
attack.
However, these studies had a cross-over design and thus
thesamepatientwastreatedwithbothdrugsinarandomized
sequence. Moreover, early treatment in our studies better
reﬂects reality compared to the artiﬁcial design of other
studieswherepatientsusuallystarttreatmentwhentheattack
intensity becomes moderate or severe. Thus, the results of
our studies are much more consistent than those of ran-
domized controlled studies with a parallel group design.
Inaddition,themostsigniﬁcantresultofourstudieswasa
more sustained relieving effect on migraine symptoms with
frovatriptan, with lower headache recurrence rates over the
48 h; these results are in line with previous reports com-
paring frovatriptan with placebo [7–9] or sumatriptan [10].
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution and reproduction in any medium, provided the original
author(s) and source are credited.
References
1. Tfelt-Hansen PC (2011) When to use frovatriptan in migraine?
J Headache Pain. doi:10.1007/s10194-011-0341-5
2. Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D
et al (2011) A double-blind, randomized, multicenter, Italian
study of frovatriptan versus rizatriptan for the acute treatment of
migraine. J Headache Pain 12:219–226
3. Bartolini M, Giamberardino MA, Lisotto C, Martelletti P,
Moscato D, Panascia B et al (2011) A double-blind, randomized,
multicenter, Italian study of frovatriptan versus almotriptan for
the acute treatment of migraine. J Headache Pain. doi:10.1007/
s10194-011-0325-5
B. Fierro (&)
Department of Neurology and Psychiatry,
University of Palermo, Palermo, Italy
e-mail: ﬁerro@unipa.it
S. Omboni
Italian Institute of Telemedicine, Varese, Italy
M. Bartolini
Department of Neuroscience,
Polytechnic University of Marche, Ancona, Italy
L. Savi  L. Pinessi
Department of Neurology,
University of Torino, Turin, Italy
123
J Headache Pain (2011) 12:395–396
DOI 10.1007/s10194-011-0347-z4. Saxena PR, Tfelt-Hansen P (2006) Triptans, 5HT1B/1D agonists
in the acute treatment of migraine. In: Olesen J, Goadsby PJ,
Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The head-
aches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia,
pp 469–503
5. Tfelt-Hansen P (2008) Frovatriptan and data publication. Head-
ache 48:1382–1383
6. Hutchinson J, Pfaffenrath V, Geraud G (2008) A randomized,
placebo-controlled, parallel-group trial of frovatriptan and
sumatriptan for a single acute migraine attack. Eur J Neurol
14(Suppl 1):144
7. Ryan R, Ge ´raud G, Goldstein J, Cady R, Keywood C (2002)
Clinical efﬁcacy of frovatriptan: placebo-controlled studies.
Headache 42(Suppl 2):S84–S92
8. Balbisi EA (2004) Frovatriptan succinate, a 5-HT1B/1D receptor
agonist for migraine. Int J Clin Pract 58:695–705
9. Ge ´raud G, Keywood C, Senard JM (2003) Migraine headache
recurrence: relationship to clinical, pharmacological, and phar-
macokinetic properties of triptans. Headache 43:376–388
10. Ge ´raud G, Spierings EL, Keywood C (2002) Tolerability and
safety of frovatriptan with short- and long-term use for treatment
of migraine and in comparison with sumatriptan. Headache
42(Suppl 2):S93–S99
396 J Headache Pain (2011) 12:395–396
123